Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706751 | 0.84 | MAPT (0.41) | MAPTHRH3SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL15551712 | 0.83 | HRH3 (0.44) | MAPTHRH3SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL25067239 | 0.81 | TP53 (0.42) | MAPTHRH3SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL22461356 | 0.80 | HRH3 (0.41) | MAPTHRH3SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1296764 | 0.80 | TSHR (0.43) | SMN1; SMN2TP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL2657918 | 0.80 | — | — | |
| SCHEMBL23396158 | 0.79 | HRH3 (0.50) | MAPTHRH3SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL485162 | 0.79 | SMN1; SMN2 (0.62) | MAPTSMN1; SMN2TP53ALDH1A1POLB | |
| SCHEMBL18039987 | 0.78 | MAPT (0.38) | MAPTHRH3SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL28017589 | 0.78 | MAPT (0.41) | MAPTHRH3ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061990-B | A kind of abiraterone derivative and preparation method thereof and medical usage | 四川海思科制药有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-105646637-B | A kind of abiraterone derivative and preparation method thereof and medical usage | 四川海思科制药有限公司 | 2018-12-14 | — | — | CN | disclosed |
| CN-106061990-A | Abiraterone derivative, and preparation method therefor and medical applications thereof | 四川海思科制药有限公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-105646637-A | Abiraterone derivative, preparation method and medical applications thereof | 四川海思科制药有限公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-2134704-B1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-09-22 | — | — | EP | disclosed |
| US-20100120807-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-05-13 | — | — | US | disclosed |
| EP-2134704-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109702-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120807-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | MAPT 3590/4885HRH3 420/4885SMN1; SMN2 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.